AstraZeneca shares hit two-month high as $2bn Summit deal strengthens oncology pipeline

AstraZeneca shares hit two-month high as $2bn Summit deal strengthens oncology pipeline

AstraZeneca shares climbed to a two-month high at 12,786 pence on Tuesday 29^th of September after the pharmaceutical group agreed to invest $2 billion in Summit Therapeutics, giving it exposure to one of the most closely watched new approaches in cancer treatment while avoiding the cost and risk of acquiring the drugmaker outright.

The deal will give AstraZeneca rights equivalent to around 12% of Summit's outstanding common stock, or approximately 10.6% on a fully diluted basis, once the preferred shares convert. AstraZeneca is paying the equivalent of $18.36 per Summit share, an almost 19% premium to Summit's previous closing price.

The investment is being accompanied by a clinical collaboration centred on ivonescimab, a potential first-in-class bispecific antibody that simultaneously targets PD-1 and VEGF. The companies plan to combine ivonescimab with AstraZeneca's experimental antibody-drug conjugate (ADC) sonesitatug vedotin, or Sone-Ve, initially in gastrointestinal cancers. They intend to start the trials imminently, while a broader memorandum of understanding envisages combining ivonescimab with additional AstraZeneca cancer medicines, including other ADCs.

The structure is important because AstraZeneca is not simply buying another drug. It is buying an option on a potentially significant oncology platform while retaining flexibility over how much capital it commits to the programme.

Those looking to invest in AstraZeneca can do so through IG Invest or our share dealing service, while traders can access the share price via spread betting or CFD trading.

A capital-light bet on a promising cancer platform

Ivonescimab is particularly interesting because it combines two established approaches in oncology in a single molecule. By blocking PD-1, it is designed to help the immune system attack cancer, while VEGF inhibition targets the blood-vessel growth that tumours rely on.

The drug was developed by China-based Akeso, which licensed rights outside China to Summit. Ivonescimab is already approved for certain patients with non-small-cell lung cancer in China, while its US application is being reviewed by the US Food and Drug Administration (FDA).

The FDA accepted Summit's application for ivonescimab in combination with chemotherapy for patients with Epidermal Growth Factor Receptor (EGFR)-mutated locally advanced or metastatic non-squamous non-small-cell lung cancer following tyrosine kinase inhibitor treatment in January. The Prescription Drug User Fee Act (PDUFA) action date is 14 November 2026, putting the regulatory decision only weeks away.

That makes AstraZeneca's timing particularly notable. Rather than waiting for regulatory approval and potentially paying considerably more for access if ivonescimab succeeds, it has secured a strategic position ahead of the decision.

At the same time, AstraZeneca is not assuming sole responsibility for developing the drug. Under the collaboration, the two companies will contribute their respective medicines and share clinical-trial costs, while retaining development and commercial rights to their own assets.

That gives AstraZeneca exposure to the upside without committing to a full acquisition of Summit or taking on the entire development risk.

Ivonescimab fits AstraZeneca's ADC strategy

The most strategically important element may ultimately be what AstraZeneca can do with ivonescimab beyond its initial lung-cancer indication.

AstraZeneca has been building a sizeable antibody-drug conjugate portfolio, with the company increasingly looking to combine Antibody-Drug Conjugates (ADCs) with next-generation immunotherapies. Sone-Ve is a CLDN18.2-targeting ADC designed to deliver a cytotoxic payload directly to cancer cells and is being developed particularly for gastrointestinal cancers.

AstraZeneca reported positive high-level Phase III results from the CLARITY-Gastric01 trial in July, saying Sone-Ve produced a statistically significant and clinically meaningful improvement in overall survival in patients with CLDN18.2-positive advanced gastric and gastroesophageal cancers. The results are due to be presented at the European Society for Medical Oncology Congress.

Combining the two technologies therefore gives AstraZeneca a potential three-pronged approach: directly attacking tumour cells with an ADC, stimulating an immune response through Programmed Cell Death (PD)-1 blockade and inhibiting tumour blood-vessel formation through Vascular Endothelial Growth Factor (VEGF) blockade.

Whether that combination ultimately produces a clinically meaningful benefit remains to be established, but the strategic logic is clear.

Why AstraZeneca is moving now

The deal also comes at an important point for AstraZeneca's broader oncology strategy.

Oncology already accounted for 46% of AstraZeneca's revenue in the first half of 2026, with sales of $14.1 billion growing 15% at constant exchange rates. Group revenue rose 6% to $30.7 billion, while core operating profit increased 11%. AstraZeneca has reiterated its ambition to generate $80 billion of annual revenue by 2030.

That growth target means the company needs to keep replenishing its pipeline even as some of its established medicines eventually face patent and competitive pressures.

The Summit investment therefore looks less like a one-off punt on an individual drug and more like another example of AstraZeneca using partnerships and minority investments to broaden its oncology options.

It is also consistent with the company's stated strategy of expanding its ADC portfolio and combining those medicines with newer forms of immunotherapy. AstraZeneca has said that PD-1/VEGF bispecifics could have potential across lung, breast and gastrointestinal cancers.

The approach offers a degree of optionality. If ivonescimab establishes itself as a major new oncology platform, AstraZeneca is already positioned to explore combinations across its own portfolio. If the drug fails to meet expectations, the company has not acquired Summit outright or committed its entire balance sheet to the asset.

November FDA decision becomes a key catalyst

The immediate focus, however, will remain on the FDA.

The 14 November PDUFA date is likely to become an important catalyst for Summit and, indirectly, AstraZeneca. A US approval would remove one of the biggest uncertainties surrounding ivonescimab and could provide further support for AstraZeneca's decision to establish a strategic relationship before the regulatory verdict.

There is nevertheless a distinction between regulatory approval and commercial success. Approval in a particular EGFR-mutated lung-cancer setting would not by itself prove that ivonescimab can become a broad oncology platform. The combination trials with AstraZeneca's ADCs will need to demonstrate that pairing the two mechanisms delivers benefits that justify changing existing treatment approaches.

That makes the new partnership more than simply a near-term FDA trade. It is effectively a way for AstraZeneca to secure a seat at the table as the PD-1/VEGF bispecific class develops.

The move also follows AstraZeneca's discontinuation of the Phase III eVOLVE-Lung02 trial of its own bispecific volrustomig in August after an independent monitoring committee concluded that the combination was unlikely to meet its primary progression-free and overall-survival endpoints in the relevant patient population.

Against that backdrop, access to an externally developed bispecific with a different mechanism could be particularly valuable.

What it means for AstraZeneca shares

The initial share-price reaction suggests investors have viewed the deal positively, with AstraZeneca gaining over 1% to reach a two-month high on Tuesday. Summit shares rose much more sharply, by around 17% pre-market, reflecting the direct financial impact of the $2 billion investment and the validation provided by a global oncology leader.

For AstraZeneca, however, the significance is less about the immediate earnings contribution and more about pipeline optionality.

The company has effectively spent $2 billion to gain a meaningful position in Summit, access to ivonescimab, and a pathway for testing the drug alongside its own ADC portfolio, while retaining the ability to decide how aggressively to expand the relationship as clinical and regulatory evidence emerges.

That makes the Summit deal a statement of intent in oncology rather than simply a bet on one November FDA decision.

AstraZeneca is signalling that it wants to participate in the emerging PD-1/VEGF bispecific market, but it is doing so without taking on the full financial and development risk of owning the underlying company.

For investors, the key question now is whether ivonescimab can convert promising clinical evidence into regulatory approval and, ultimately, a commercially meaningful oncology franchise. The November FDA decision could provide the first major answer.

AstraZeneca analyst ratings and technical analysis

Analysts rate AstraZeneca as a ‘buy’ with a mean long-term price target at 15,282.90p, around 21% above the current share price (as of 29 September 2026).

TipRanks have given AstraZeneca their highest ’10 Outperform’ Smart Score and rate the pharmaceutical company as a ‘strong buy’.

For the AstraZeneca share price to regain some or all of its year-to-date 7% loss it ideally needs to rise above its late July high at 13,164p. If this level, the September 2024 peak at 13,388p and the next higher 200-day simple moving average (SMA) at 13,582p were to be exceeded on a daily chart closing basis, an attempt to reach this year’s February all-time high at 15,730p might be made.

AstraZeneca daily candlestick chart

While the AstraZeneca share price stays above its 2020-to-2026 long-term uptrend line at 10,618p and, more importantly its July 2026 low at 10,524p, the above bullish scenario is expected to eventually play out.

AstraZeneca monthly candlestick chart

Failure at the 10,524p July trough would likely lead to the June 2022-to-May 2025 lows at 9,670p-to-9,399p being revisited, though.

How to invest in AstraZeneca shares

1. Do your research on AstraZeneca, the Summit deal and the key catalysts including the 14 November FDA decision for ivonescimab
2. Download IG Invest or open a share dealing account with us
3. Search for AstraZeneca (AZN) in our platform or app
4. Choose the number of shares or value of money you'd like to invest
5. Place your trade